Co-Diagnostics Inc Registered Shs CODX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
-
Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
-
Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
-
Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
-
Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
-
Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
-
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
-
Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
Trading Information
- Previous Close Price
- $0.65
- Day Range
- $0.61–0.67
- 52-Week Range
- $0.61–46.50
- Bid/Ask
- $0.62 / $0.64
- Shares Outstanding
- 6.98M
- Market Cap
- $4.48M
- Volume/Avg
- 715,219 / 362,801
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 115
- Website
- https://www.codiagnostics.com
Valuation
|
Metric
|
CODX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.25 |
Price/Sales | 2.18 |
Price/Cash Flow | — |
Price/Earnings
CODX
Financial Strength
|
Metric
|
CODX
|
|---|---|
Quick Ratio | 1.29 |
Current Ratio | 1.81 |
Interest Coverage | — |
Quick Ratio
CODX
Profitability
|
Metric
|
CODX
|
|---|---|
Return on Assets (Normalized) | −30.74% |
Return on Equity (Normalized) | −36.32% |
Return on Invested Capital (Normalized) | −35.18% |
Return on Assets
CODX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|SdwlZ&! | LOCK|w>!h | $174B | |||
| Medtronic PLC
MDT
| LOCK|c@f^@lK | LOCK|S$R$g | $119B | |||
| Stryker Corp
SYK
| LOCK|Wm!&?kG | LOCK|Dj | $114B | |||
| Boston Scientific Corp
BSX
| LOCK|?p>z^?S | LOCK|yqsJ | $65B | |||
| Edwards Lifesciences Corp
EW
| LOCK|^Fx!H$& | LOCK|l@&G | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|WGDKYg | LOCK|JDC | $32B | |||
| DexCom Inc
DXCM
| LOCK|$jlL!<j% | LOCK|KZv@& | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|g#r | LOCK|vq | $25B | |||
| Steris PLC
STE
| LOCK|FfqhwLJ | LOCK|@btR^ | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|m>K@kLqQ | LOCK|M& | $18B |
United States